AEROVATE THERAPEUTICS INC

$24.75 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About AEROVATE THERAPEUTICS INC

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The Company's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The Company has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. It anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

Stock Analysis

last close $25
1-mo return 61.9%
3-mo return 115.9%
avg daily vol. 149.3T
52-week high 27.83
52-week low 7.74
market cap. $610M
forward pe -
annual div. -
roe -42.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe